Corporate Update on Shanghai Fosun Pharmaceutical Group Co. Ltd.

Regulatory Milestone for Novel KAT6A/B Inhibitor

Shanghai Fosun Pharmaceutical Group Co. Ltd. (hereafter “Fosun”), a listed health‑care enterprise on the Hong Kong Stock Exchange, has announced that a small‑molecule inhibitor developed by its subsidiary, Shanghai Fu Hong Hanlin Biotechnology Co. Ltd. (hereafter “Fu Hong Hanlin”), has obtained approval from China’s State Drug Administration (SDA) to initiate a phase‑I clinical trial. The trial will enroll patients with advanced or metastatic solid tumours and will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of the KAT6A/B inhibitor.

Scientific Rationale

KAT6A/B in Tumor Biology KAT6A (lysine acetyltransferase 6A, also known as MYST4) and its paralog KAT6B are histone acetyltransferases (HATs) that catalyze acetylation of lysine residues on histone H3 and H4. This post‑translational modification relaxes chromatin structure, thereby facilitating transcriptional elongation and the expression of oncogenic drivers. In multiple malignancies—including acute myeloid leukemia, myelodysplastic syndromes, and solid tumours such as colorectal, pancreatic, and non‑small‑cell lung cancer—overexpression or chromosomal translocations involving KAT6A/B have been associated with poor prognosis and therapy resistance.

The inhibitor developed by Fu Hong Hanlin is a highly selective, ATP‑competitive agent that binds the catalytic pocket of KAT6A/B, blocking acetyltransferase activity. Preclinical studies in xenograft models have shown:

  • Dose‑dependent suppression of histone H3 acetylation at KAT6A/B target sites, leading to transcriptional down‑regulation of MYC and other oncogenic transcription factors.
  • Tumor regression in KAT6A‑amplified breast cancer models, with a median objective response rate (ORR) of 32 % in a 12‑week period.
  • Synergistic activity when combined with PI3K/AKT pathway inhibitors, suggesting a potential combination strategy for future trials.

These mechanistic insights support the hypothesis that pharmacological inhibition of KAT6A/B can re‑program the epigenetic landscape of tumour cells, rendering them more susceptible to apoptosis and less capable of sustaining proliferation.

Phase‑I Trial Design

  • Objective: Establish the maximum tolerated dose (MTD), dose‑limiting toxicities (DLTs), and recommended phase‑II dose (RP2D) while collecting PK and preliminary efficacy data.
  • Population: Adults (≥ 18 years) with histologically confirmed, advanced or metastatic solid tumours refractory to standard therapies, and with measurable disease per RECIST v1.1.
  • Dose Escalation: Traditional 3 + 3 design, starting at 50 mg once daily, escalating in 20‑mg increments until DLTs occur in ≥ 2/6 patients.
  • Endpoints: Safety (adverse events graded by CTCAE v5.0), PK parameters (Cmax, Tmax, AUC), pharmacodynamic markers (global histone acetylation levels in tumour biopsies), and ORR per RECIST.
  • Duration: Approximately 24 months, with an interim analysis after the first cohort of 12 patients to assess safety and PK.

Regulatory Pathway Considerations

The SDA approval for a phase‑I trial is the first of several regulatory steps required before commercialization:

  1. Pre‑IND Consultation – The company previously engaged the SDA in a pre‑Investigational New Drug (IND) meeting to align on trial design and preclinical data requirements.
  2. IND Submission – A detailed IND dossier, including Chemistry, Manufacturing, and Controls (CMC), preclinical toxicology, and proposed clinical protocol, will be filed in the forthcoming quarter.
  3. Phase‑II/III Development – If the phase‑I trial demonstrates acceptable safety and preliminary efficacy, the company will pursue accelerated approval pathways (e.g., Fast Track, Breakthrough Therapy designation) depending on the tumour indication and patient population.
  4. Post‑Marketing Commitments – Long‑term safety surveillance and real‑world evidence studies will be required to sustain market access, especially for a first‑in‑class epigenetic inhibitor.

Corporate and Market Context

Fosun’s board confirmed the accuracy of the announcement, emphasizing that the phase‑I trial is an early milestone and that additional clinical studies and regulatory approvals are prerequisites for market entry. The group disclosed that it has provided financial guarantees to Fu Hong Hanlin, underscoring a commitment to the subsidiary’s R&D trajectory.

In the broader Hong Kong pharmaceutical sector, recent trading sessions have been buoyant, with several peer companies—such as China Resources Sanji, China National Pharmaceutical Group, and Innovent Biologics—registering gains. This supportive environment reflects investor confidence in China’s growing biopharmaceutical pipeline and the potential for novel therapeutics to address unmet oncologic needs.

Outlook

While the phase‑I trial will provide critical safety and pharmacodynamic data, the path to commercialization remains contingent on multiple factors:

  • Efficacy Signals: Robust ORR or disease‑control rates will accelerate progression to phase II.
  • Biomarker Validation: Identification of predictive biomarkers (e.g., KAT6A/B expression levels or gene fusions) could enable patient stratification and improve trial outcomes.
  • Competitive Landscape: Emerging KAT6 inhibitors from other developers may influence strategic decisions, including potential collaborations or licensing agreements.
  • Regulatory Momentum: Timely submission of IND and favorable assessments will dictate the speed of clinical development.

Fosun’s commitment to advancing a novel KAT6A/B inhibitor reflects its broader strategy to build a diversified therapeutic portfolio within oncology. Stakeholders will closely monitor the trial’s safety profile, PK/PD correlations, and early efficacy signals to gauge the compound’s translational potential.